Decentralized Trials Are Better Understood, But 5 Misconceptions Persist

While decentralized clinical trials (DCTs) have existed for almost 20 years, some CROs and sponsors still hesitate to use the research method for a variety of reasons. These concerns most commonly relate to safety, complexity, capacity, control, and cost, and often lead to discomfort due to a lack of familiarity.

Since the COVID-19 pandemic, however, DCTs have become more understood. Sponsors who would never have considered a DCT in the past were suddenly flocking to DCT service providers in desperate efforts to rescue their drug trials.

Despite these efforts and the industry shift, persistent misconceptions about DCT remain and continue to stand in the way of wider adoption and the benefits they bring, including making potentially life-saving drugs more accessible to a more diverse range of trial participants.

Discover how one mobile research services and clinical trials provider addresses these matters.